Kengo Ohashi

Kengo Ohashi

Auto-generated profile, based on publicly available information

Kengo Ohashi

Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
YSYasutaka Shinoda
Yasutaka Shinoda
YFYasuyuki Fukami
Yasuyuki Fukami
JSJoe Shindoh
Joe Shindoh
TSTadashi Sugiyama
Tadashi Sugiyama

24 January 2019 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
YSYasutaka Shinoda
Yasutaka Shinoda
TMTakayuki Mori
Takayuki Mori
SYShinya Yoshida
Shinya Yoshida
TSTadashi Sugiyama
Tadashi Sugiyama

23 December 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
YSYasutaka Shinoda
Yasutaka Shinoda
TTTakamasa Takahashi
Takamasa Takahashi
HSHiroaki Shikano
Hiroaki Shikano
EUEiseki Usami
Eiseki Usami

9 May 2025 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
KOKengo Ohashi
Kengo Ohashi
YSYasutaka Shinoda
Yasutaka Shinoda
TMTomoko Matsuoka
Tomoko Matsuoka
KAKaori Arai
Kaori Arai
NHNao Hotta
Nao Hotta
EUEiseki Usami
Eiseki Usami
Multidrug-resistant bacteria pose a major challenge in healthcare, and antimicrobial stewardship teams (ASTs) play a crucial role in optimizing antimicrobial use, particularly for last-resort drugs like meropenem (MEPM) and tazobactam/piperacillin (TAZ/PIPC). This study evaluated the impact of enhanced interventions, which included a hospital-wide policy restricting MEPM and TAZ/PIPC use to 5 d and mandating pre-treatment culture testing. A before-and-after study was conducted at a public hospital in Japan, comparing the pre- (June 2021–May 2022) and post-enhanced intervention (June 2022–May 2023) periods. The primary outcome was days of therapy (DOT) per 1000 patient days for MEPM and TAZ/PIPC. Secondary outcomes included antimicrobial use density (AUD), monthly number of patients receiving MEPM and TAZ/PIPC, 30-d mortality, and AST intervention proposals. Overall, 1896 patients received MEPM (pre: 591; post: 527) or TAZ/PIPC (pre: 411; post: 367). As a result, MEPM DOT decreased from 19.4 to 17.2 per 1000 patient days (p = 0.019), and AUD from 14.4 to 11.7 defined daily doses per 1000 patient days (p = 0.017). TAZ/PIPC DOT remained unchanged (p = 0.219), while AUD decreased from 8.7 to 7.6 (p = 0.046). Furthermore, the monthly number of patients receiving MEPM and TAZ/PIPC and their 30-d mortality showed no significant change. AST proposals increased from 209 to 359 for MEPM and from 116 to 238 for TAZ/PIPC (both p < 0.001). In conclusion, enhanced interventions effectively reduced MEPM use without increasing TAZ/PIPC use or worsening 30-d mortality, suggesting that structured guidelines may enhance antimicrobial stewardship in resource-limited settings.

28 November 2024 in Journal of Pharmaceutical Health Care and Sciences
Verified
Journal Article
Open access
PDF file
YSYasutaka Shinoda
Yasutaka Shinoda
KOKengo Ohashi
Kengo Ohashi
TMTomoko Matsuoka
Tomoko Matsuoka
KAKaori Arai
Kaori Arai
NHNao Hotta
Nao Hotta
EUEiseki Usami
Eiseki Usami
Background: Aminoglycosides are crucial for treating multidrug-resistant gram-negative infections and endocarditis. However, aminoglycosides are associated with significant risks of nephrotoxicity, necessitating careful dose selection and therapeutic drug monitoring. Therapeutic drug monitoring is essential for minimizing risk; however, few institutions routinely perform it. This study aimed to assess the impact of a pharmacist-driven therapeutic drug monitoring intervention on aminoglycoside usage trends and clinical outcomes. Methods: This retrospective cohort study included 263 patients treated with aminoglycosides between 2014 and 2023. A pharmacist-led therapeutic drug monitoring intervention began in 2017, focusing on monitoring renal function, documenting patient weight, and closely managing aminoglycoside concentrations. Trends in aminoglycoside use and renal outcomes were analyzed. Results: Over the study period, appropriate use of aminoglycosides at the time of initial prescription increased from 49 to 82% (P < 0.01). Pharmacist dosing design at initial prescription increased significantly from 21% pre-intervention to 60% post-intervention (P < 0.01). The proportion of pharmacist intervention in initial dosing design increased over time. The proportion of patients with measured aminoglycoside blood concentrations significantly increased from 53% pre-intervention to 72% post-intervention (P < 0.01). The proportion of patients who were able to manage target blood concentrations from the initial aminoglycoside dose without dose adjustments increased from 31% pre-intervention to 42% post-intervention, although the results were not significantly different (P = 0.07). The incidence rate of renal impairment remained similar (11% vs. 12%; P = 0.85), although the annual average number of cases decreased from 4.3 before the intervention to 2.5 after. Similarly, there were no significant differences in clinical efficacy before and after the intervention (65% vs. 71%; P = 0.35). Furthermore, aminoglycoside stewardship led to a 56% cost saving. Conclusions: Pharmacist-led aminoglycoside stewardship significantly improved the appropriate use of aminoglycosides and decreased the associated costs. Thus, pharmacist involvement is essential for the proper use of aminoglycosides. However, many patients required aminoglycoside dose reductions despite the pharmacist’s guideline-based dosing design. Therefore, further accumulation of information on the management of aminoglycoside blood concentration may be necessary for the revision of these guidelines.

23 June 2026 in Journal of Hospital Infection
Verified
Journal Article
Closed access
KOKengo Ohashi
Kengo Ohashi
YSYasutaka Shinoda
Yasutaka Shinoda
TMTomoko Matsuoka
Tomoko Matsuoka
KAKaori Arai
Kaori Arai
NHNao Hotta
Nao Hotta
EUEiseki Usami
Eiseki Usami